JLABS Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge
- Johnson & Johnson Innovation (JLABS)
- Projectes de recerca
- FSJd end:
JLABS periodically launches JLABS QuickFire Challenges. These global challenges support working with local partners for innovation and empower innovative scientists, companies and entrepreneurs to seek comprehensive and integrated solutions that hold the potential of improving the health of people around the world, particularly in areas of significant global impact on people's health. These competitions call for early-stage innovators to apply for a chance to win research grants, access to lab spaces, exposure to the innovation community and other startups, global industry networking opportunities, mentorship and coaching from Johnson & Johnson Innovation and its partners.
The 'JLABS Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge' calls on innovators to submit ideas aimed at optimising AL amyloidosis disease detection and early diagnosis. The challenge is organised by JLABS together with the Janssen Global Services.
JLABS encourages innovators to submit potentially ground-breaking ideas in:
- Increase awareness of disease symptoms and improve recognition of disease among HCPs.
- Improve identification/testing of patients.
- Develop blood test/biomarkers for AL amyloidosis.
- Imagine nuclear medicine with amyloid-specific tracers.
- Create AI-based screening tools.
- Facilitate EMR-based research.
- Produce Epidemiology studies.
JLABS is interrested in products, technologies, or methodologies, which may be translational or clinical in nature.
Within the framework of the challenge, the following awards are available:
- Multiple grants in increments up to $250,000, $150,000, and $50,000.
- Access to the Johnson & Johnson Innovation - JLABS ecosystem.
- Mentorship from experts of the Johnson & Johnson Family of Companies.
Eligible applicants are innovators from around the world. Eligible applicants include entrepreneurs/startups, haematologists, cardiologists, radiologists, and nephrologists familiar with AL amyloidosis, basic science researchers, and patient advocates.